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3Migraine is a debilitating neurological disorder affecting around 1 in 7 people worldwide,92
but its molecular mechanisms remain poorly understood. Some debate exists over93
whether migraine is a disease of vascular dysfunction or a result of neuronal dysfunction94
with secondary vascular changes. Genome-wide association (GWA) studies have thus far95
identified 13 independent loci associated with migraine. To identify new susceptibility96
loci, we performed the largest genetic study of migraine to date, comprising 59,674 cases97
and 316,078 controls from 22 GWA studies. We identified 44 independent single98
nucleotide polymorphisms (SNPs) significantly associated with migraine risk (P < 5 × 10-99
8) that map to 38 distinct genomic loci, including 28 loci not previously reported and the100
first locus identified on chromosome X. In subsequent computational analyses, the101
identified loci showed enrichment for genes expressed in vascular and smooth muscle102
tissues, consistent with a predominant theory of migraine that highlights vascular103
etiologies.104
105
Migraine is ranked as the third most common disease worldwide, with a lifetime prevalence of106
15-20%, affecting up to one billion people across the globe1,2. It ranks as the 7th most disabling107
of all diseases worldwide (or 1st most disabling neurological disease) in terms of years of life lost108
to disability1 and is the 3rd most costly neurological disorder after dementia and stroke3. There is109
debate about whether migraine is a disease of vascular dysfunction, or a result of neuronal110
dysfunction with vascular changes representing downstream effects not themselves causative111
of migraine4,5. However, genetic evidence favoring one theory versus the other is lacking. At the112
phenotypic level, migraine is defined by diagnostic criteria from the International Headache113
Society6. There are two prevalent sub-forms: migraine without aura is characterized by recurrent114
attacks of moderate or severe headache associated with nausea or hypersensitivity to light and115
sound. Migraine with aura is characterized by transient visual and/or sensory and/or speech116
symptoms usually followed by a headache phase similar to migraine without aura.117
118
Family and twin studies estimate a heritability of 42% (95% confidence interval [CI] = 36-47%)119
for migraine7, pointing to a genetic component of the disease. Despite this, genetic association120
studies have revealed relatively little about the molecular mechanisms that contribute to121
pathophysiology. Understanding has been limited partly because, to date, only 13 genome-wide122
significant risk loci have been identified for the prevalent forms of migraine8–11. In familial123
hemiplegic migraine (FHM), a rare Mendelian form of the disease, three ion transport-related124
genes (CACNA1A, ATP1A2 and SCN1A) have been implicated12–14. These findings suggest that125
4mechanisms that regulate neuronal ion homeostasis might also be involved in migraine more126
generally, however, no genes related to ion transport have yet been identified for these more127
prevalent forms of migraine15.128
129
We performed a meta-analysis of 22 genome-wide association (GWA) studies, consisting of130
59,674 cases and 316,078 controls collected from six tertiary headache clinics and 27131
population-based cohorts through our worldwide collaboration in the International Headache132
Genetics Consortium (IHGC). This combined dataset contained over 35,000 new migraine133
cases not included in previously published GWA studies. Here we present the findings of this134
new meta-analysis, including 38 genomic loci, harboring 44 independent association signals135
identified at levels of genome-wide significance, which support current theories of migraine136
pathophysiology and also offer new insights into the disease.137
138
Results139
Significant associations at 38 independent genomic loci140
The primary meta-analysis was performed on all migraine samples available through the IHGC,141
regardless of ascertainment. These case samples included both individuals diagnosed with142
migraine by a doctor as well as individuals with self-reported migraine via questionnaires. Study143
design and sample ascertainment for each individual study is outlined in the Supplementary144
Note (and summarized in Supplementary Table 1). The final combined sample consisted of145
59,674 cases and 316,078 controls in 22 non-overlapping case-control samples (Table 1). All146
samples were of European ancestry. Before including the largest study from 23andMe, we147
confirmed that it did not contribute any additional heterogeneity compared to the other148
population and clinic-based studies (Supplementary Table 2).149
150
The 22 individual GWA studies completed standard quality control protocols (Online Methods)151
summarized in Supplementary Table 3. Missing genotypes were then imputed into each152
sample using a common 1000 Genomes Project reference panel16. Association analyses were153
performed within each study using logistic regression on the imputed marker dosages while154
adjusting for sex and other covariates where necessary (Online Methods and Supplementary155
Table 4). The association results were combined using an inverse-variance weighted fixed-156
effects meta-analysis. Markers were filtered for imputation quality and other metrics (Online157
Methods) leaving 8,094,889 variants for consideration in our primary analysis.158
5159
Among these variants in the primary analysis, we identified 44 genome-wide significant SNP160
associations (P < 5 × 10-8) that are independent (r2 < 0.1) with regards to linkage disequilibrium161
(LD). We validated the 44 SNPs by comparing genotypes in a subset of the sample to those162
obtained from whole-genome sequencing (Supplementary Table 5). To help identify candidate163
risk genes from these, we defined an associated locus as the genomic region bounded by all164
markers in LD (r2 > 0.6 in 1000 Genomes, Phase I, EUR individuals) with each of the 44 index165
SNPs and in addition, all such regions in close proximity (< 250 kb) were merged. From these166
defined regions we implicate 38 distinct genomic loci in total for the prevalent forms of migraine,167
28 of which have not previously been reported (Figure 1).168
169
These 38 loci replicate 10 of the 13 previously reported genome-wide associations to migraine170
(Table 2). Six of the 38 loci contain a secondary genome-wide significant SNP (P < 5 × 10-8) not171
in LD (r2 < 0.1) with the top SNP in the locus (Table 2). Five of these secondary signals were172
found in known loci (at LRP1, PRDM16, FHL5, TRPM8, and TSPAN2), while the sixth was173
found within one of the 28 new loci (PLCE1). Therefore, out of the 44 LD-independent SNPs174
reported here, 34 are new associations to migraine. Three previously reported loci that were175
associated to subtypes of migraine (rs1835740 near MTDH to migraine with aura, rs10915437176
near AJAP1 to migraine clinical-samples, and rs10504861 near MMP16 to migraine without177
aura)8,11 show only nominal significance in the current meta-analysis (P = 5 × 10-3 for178
rs1835740, P = 4.4 × 10-5 for rs10915437, and P = 4.9 × 10-5 for rs10504861, Supplementary179
Table 6), however, these loci have since been shown to be associated to specific phenotypic180
features of migraine17 and therefore may require a more phenotypically homogeneous sample181
to be accurately assessed for association. Four out of 44 SNPs (at TRPM8, ZCCHC14, MRVI1,182
and CCM2L) exhibited moderate heterogeneity across the individual GWA studies (Cochran’s Q183
test p-value < 0.05, Supplementary Table 7) therefore at these markers we applied a random184
effects model18.185
186
Characterization of the associated loci187
In total, 32 of 38 (84%) loci overlap with transcripts from protein-coding genes, and 17 (45%) of188
these regions contain just a single gene (see Supplementary Figure 1 for regional plots of the189
38 genomic loci and Supplementary Table 8 for extended information on each locus). Among190
the 38 loci, only two contain ion channel genes (KCNK519 and TRPM820). Hence, despite191
previous hypotheses of migraine as a potential channelopathy5,21, the loci identified to date do192
6not support common variants in ion channel genes as strong susceptibility components in193
prevalent forms of migraine. However, three other loci do contain genes involved more generally194
in ion homeostasis (SLC24A322, ITPK123, and GJA124, Supplementary Table 9).195
196
Several of the genes have previous associations to vascular disease (PHACTR1,25,26197
TGFBR2,27 LRP1,28 PRDM16,29 RNF213,30 JAG1,31 HEY2,32 GJA133, ARMS234), or are198
involved in smooth muscle contractility and regulation of vascular tone (MRVI1,35 GJA1,36199
SLC24A3,37 NRP138). Three of the 44 migraine index SNPs have previously reported200
associations in the National Human Genome Research Institute (NHGRI) GWAS catalog at201
exactly the same SNP (rs9349379 at PHACTR1 with coronary heart disease39–41, coronary202
artery calcification42, and cervical artery dissection; rs11624776 at ITPK1 with thyroid hormone203
levels43; and rs11172113 at LRP1 with pulmonary function; Supplementary Table 10). Six of204
the loci harbor genes that are involved in nitric oxide signaling and oxidative stress (REST44,205
GJA145, YAP146, PRDM1647, LRP148, and MRVI149).206
207
From each locus we chose the nearest gene to the index SNP to assess gene expression208
activity in tissues from the GTEx consortium (Supplementary Figure 2). While we found that209
most of the putative migraine loci genes were expressed in many different tissue types, we210
could detect tissue specificity in certain instances whereby some genes showed significantly211
higher expression in a particular tissue group relative to the others. For instance four genes212
were more actively expressed in brain (GPR149, CFDP1, DOCK4, and MPPED2) compared to213
other tissues, whereas eight genes were specifically active in vascular tissues (PRDM16,214
MEF2D, FHL5, C7orf10, YAP1, LRP1, ZCCHC14, and JAG1). Many of the other putative215
migraine loci genes were actively expressed in more than one tissue group.216
217
Genomic inflation and LD-score regression analysis218
To assess whether the 38 loci harbor true associations with migraine rather than reflecting219
systematic differences between cases and controls (such as population stratification) we220
analyzed the genome-wide inflation of test statistics in our primary meta-analysis. As expected221
for a complex polygenic trait, the distribution of test statistics deviates from the null (genomic222
inflation factor λGC = 1.24, Supplementary Figure 3) which is in line with other large GWA study223
meta-analyses50–53. Since much of the inflation in a polygenic trait arises from LD between the224
causal SNPs and many other neighboring SNPs in the local region, we LD-pruned the meta-225
analysis results to create a set of LD-independent markers (i.e. in PLINK54 with a 250-kb sliding226
7window and r2 > 0.2). The resulting genomic inflation was reduced (λGC = 1.15, Supplementary227
Figure 4) and likely reflects the inflation remaining due to the polygenic signal at many228
independent loci, including those not yet significantly associated.229
230
To confirm that the observed inflation is primarily coming from true polygenic signal, we231
analyzed the meta-analysis results from all imputed markers using LD-score regression55. This232
method tests for a linear relationship between marker test statistics and LD score, defined as233
the sum of r2 values between a marker and all other markers within a 1-Mb window. The primary234
analysis results show a linear relationship between association test statistics and LD-score235
(Supplementary Figure 5) and estimate that the majority (88.2%) of the inflation in test236
statistics can be ascribed to true polygenic signal rather than population stratification or other237
confounders. These results are consistent with the theory of polygenic disease architecture238
shown previously by both simulation and real data for GWAS samples of similar size56.239
240
Migraine subtype analyses241
To elucidate pathophysiological mechanisms underpinning the migraine aura, we performed a242
secondary analysis by creating two subsets that included only samples with the subtypes;243
migraine with aura and migraine without aura. These subsets only included those studies where244
sufficient information was available to assign a diagnosis of either subtype according to245
classification criteria standardized by the International Headache Society (IHS)6. For the246
population-based study samples this involved questionnaires, whereas for the clinic-based247
study samples the diagnosis was assigned on the basis of a structured interview by telephone248
or in person. A stricter diagnosis is required for these migraine subtypes as the migraine aura249
specifically is challenging to distinguish from other neurological features that can present as250
symptoms from unrelated conditions.251
252
As a result, the migraine subtype analyses consisted of considerably smaller sample sizes253
compared to the main analysis (6,332 cases vs. 144,883 controls for migraine with aura and254
8,348 cases vs. 139,622 controls for migraine without aura, see Table 1). As with the primary255
migraine analysis, the test statistics for migraine with aura or migraine without aura were256
consistent with underlying polygenic architecture rather than other potential sources of inflation257
(Supplementary Figure 6 and 7). For the migraine without aura subset analysis we found258
seven independent genomic loci (near TSPAN2, TRPM8, PHACTR1, FHL5, ASTN2, near259
FGF6, and LRP1) to be significantly associated (Supplementary Table 11 and Supplementary260
8Figure 8). All seven of these loci were already identified in the primary analysis of ‘all migraine’261
types, possibly reflecting the fact that migraine without aura is the most common form of262
migraine (around 2 in 3 cases) and likely drives the association signals in the primary analysis.263
Notably, no loci were associated to migraine with aura in the other subset analysis264
(Supplementary Figure 9).265
266
To investigate whether excess heterogeneity could be contributing to the lack of associations in267
migraine with aura, we performed a heterogeneity analysis between the two subgroups. First we268
created two subsets of the migraine with aura and migraine without aura datasets from which269
none of the case or control individuals were overlapping (Supplementary Table 12). Then we270
selected the 44 LD-independent SNPs associated from the primary analysis and used a271
random-effects model to combine the migraine with aura and migraine without aura samples in272
a meta-analysis that allows for heterogeneity between the two migraine groups57. We found little273
heterogeneity with only seven of the 44 SNPs (at REST, MPPED2, PHACTR1, ASTN2, MEF2D,274
PLCE1, and MED14) exhibiting some signs of heterogeneity across subtype groups275
(Supplementary Table 13).276
277
Credible sets of markers within each locus278
For each of the 38 migraine-associated loci, we defined a credible set of markers that could279
plausibly be considered as causal using a Bayesian-likelihood based approach58. This method280
incorporates evidence from association test statistics and the LD structure between SNPs in a281
locus (Online Methods). A list of the credible set SNPs obtained for each locus is provided in282
Supplementary Table 14. We found three instances (in RNF213, PLCE1, and MRVI1) where283
the association signal could be credibly attributed to exonic missense polymorphisms284
(Supplementary Table 15). However, most of the credible markers at each locus were either285
intronic or intergenic, which is consistent with the theory that most variants detected by GWA286
studies involve regulatory effects on gene expression rather than disrupting protein287
structure59,60.288
289
Overlap with eQTLs in specific tissues290
To try to identify specific migraine loci that might influence gene expression, we used previously291
published datasets that catalog expression quantitative trait loci (eQTLs) in either of two292
microarray-based studies from peripheral venous blood (N1 = 3,754) or from human brain cortex293
tissue (N2 = 550). Additionally, we used a third study based on RNAseq data from a collection of294
942 tissues and three cell lines (N3 = 1,641) from the Genotype-Tissue Expression (GTEx)295
consortium61. While this data has the advantage of a diverse tissue catalog, the number of296
samples per tissue is relatively small (Supplementary Table 16) compared to the two297
microarray datasets, possibly resulting in reduced power to detect significant eQTLs in some298
tissues. Using these datasets we applied a method based on the overlap of migraine and eQTL299
credible sets to identify eQTLs that could explain associations at the 38 migraine loci (Online300
Methods). This approach merged the migraine credible sets defined above with credible sets301
from cis-eQTL signals within a 1-Mb window and tested if the association signals between the302
migraine and eQTL credible sets were correlated. After adjusting for multiple testing we found303
no plausible eQTL associations in the peripheral blood or brain cortex data (Supplementary304
Tables 17-18 and Supplementary Figure 10). In GTEx, however, we found evidence for305
overlap from eQTLs in three tissues (Lung, Tibial Artery, and Aorta) at the HPSE2 locus and in306
one tissue (Thyroid) at the HEY2 locus (Supplementary Table 19 and Supplementary Figure307
15).308
309
In summary, from three datasets we implicate eQTL signals at only two loci (HPSE2, and310
HEY2). This low number (two out of 38) is consistent with previous studies which have observed311
that available eQTL catalogues currently lack sufficient tissue specificity and developmental312
diversity to provide enough power to provide meaningful biological insight52. No plausibly causal313
eQTLs were observed in expression data from brain.314
315
Gene expression enrichment in specific tissues316
To understand if the 38 migraine loci as a group are enriched for expression in certain tissue317
groups, we again used the GTEx pilot data61. This time we tested whether genes near to318
credibly causal SNPs at the 38 migraine loci were significantly enriched for expression in certain319
tissues (Online Methods). We found four tissues that were significantly enriched (after320
Bonferroni correction) for expression of the migraine genes (Figure 2). The two most strongly321
enriched tissues were part of the cardiovascular system; the aorta and tibial artery. Two other322
significant tissues were from the digestive system; esophagus muscularis and esophageal323
mucosa. We replicated these enrichment results in an independent dataset using a component324
of the DEPICT62 tool that conducts a tissue-specific enrichment analysis on microarray-based325
gene expression data (Supplementary Methods). DEPICT highlighted four tissues (Figure 3326
and Supplementary Table 20) with significant enrichment of genes within the migraine loci;327
10
arteries (P = 1.58 × 10-5), the upper gastrointestinal tract (P = 2.97 × 10-3), myometrium (P =328
3.03 × 10-3), and stomach (P = 3.38 × 10-3).329
330
Taken together, the expression analyses implicate arterial and gastrointestinal (GI) tissues. To331
discover if this enrichment signature could be attributed to a more specific type of smooth332
muscle, we examined the expression of the nearest genes at migraine loci in a panel of 60333
types of human smooth muscle tissue63. Overall, migraine loci genes were not significantly334
enriched in a particular class of smooth muscle (Supplementary Figures 11-13). This suggests335
that the enrichment of migraine disease variants in genes expressed in tissues with a smooth336
muscle component is not specific to blood vessels, the stomach or GI tract, but rather appears337
to be generalizable across vascular and visceral smooth muscle types.338
339
Combined, these results suggest that some of the genes affected by migraine-associated340
variants are highly expressed in vascular tissues and their dysfunction could play a role in341
migraine. Furthermore, the enrichment results suggest that other tissue types (e.g. smooth342
muscle) could also play a role and this may become evident once more migraine loci are343
discovered.344
345
Enrichment in tissue-specific enhancers346
To further assess the hypothesis that migraine variants might operate via effects on gene-347
regulation, we investigated the degree of overlap with histone modifications. We identified348
candidate causal variants underlying the 38 migraine loci, and examined their enrichment within349
cell-type specific enhancers from 56 primary human tissues and cell types from the Roadmap350
Epigenomics64 and ENCODE projects65 (Online Methods and Supplementary Table 21).351
Candidate causal variants showed highest enrichment in tissues from the mid-frontal lobe and352
duodenum smooth muscle, but these enrichments were not significant after adjusting for353
multiple testing (Figure 4).354
355
Gene set enrichment analyses356
To implicate underlying biological pathways involved in migraine, we applied a Gene Ontology357
(GO) over-representation analysis of the 38 migraine loci (Online Methods). We found nine358
vascular-related biological function categories that are significantly enriched after correction for359
multiple testing (Supplementary Table 22). Interestingly, we found little statistical support from360
the identified loci for some molecular processes that have been previously linked to migraine,361
11
e.g. ion homeostasis, glutamate signaling, serotonin signaling, nitric oxide signaling, and362
oxidative stress (Supplementary Table 23). However, it is possible that the lack of enrichment363
for these functions may be explained by recognizing that current annotations for many genes364
and pathways are far from comprehensive, or that larger numbers of migraine loci need to be365
identified before we have sensitivity to detect enrichment in these mechanisms.366
367
For a more comprehensive pathway analysis we used DEPICT, which incorporates gene co-368
expression information from microarray data to implicate additional, functionally less well-369
characterized genes in known biological pathways, protein-protein complexes and mouse370
phenotypes62 (by forming so-called ‘reconstituted gene sets’). From DEPICT we identified 67371
reconstituted gene sets that are significantly enriched (FDR < 5%) for genes found among the372
38 migraine associated loci (Supplementary Table 24). Because the reconstituted gene sets373
had genes in common, we clustered them into 10 distinct groups of gene sets (Figure 5 and374
Online Methods). Several gene sets, including the most significantly enriched reconstituted375
gene set (Abnormal Vascular Wound Healing; P = 1.86 × 10-6), were grouped into clusters376
related to cell-cell interactions (ITGB1 PPI, Adherens Junction, Integrin Complex). Several of377
the other gene set clusters were also related to vascular-biology (Figure 5 and Supplementary378
Table 24).379
380
Discussion381
In what is the largest genetic study of migraine to date, we identified 38 distinct genomic loci382
harboring 44 independent susceptibility markers for the prevalent forms of migraine. We provide383
evidence that migraine-associated genes are involved both in arterial and smooth muscle384
function. Two separate analyses, the DEPICT and the GTEx gene-expression enrichment385
analyses, point to vascular and smooth muscle tissues being involved in common variant386
susceptibility to migraine. The vascular finding is consistent with known co-morbidities and387
previously reported shared polygenic risk between migraine, stroke and cardiovascular388
diseases66,67. Furthermore, a recent GWA study of Cervical Artery Dissection (CeAD) identified389
a genome-wide significant association at exactly the same index SNP (rs9349379) as is390
associated to migraine in the PHACTR1 locus, suggesting the possibility of partially shared391
genetic components between migraine and CeAD26. These results suggest that vascular392
dysfunction and possibly also other smooth muscle dysfunction likely play roles in migraine393
pathogenesis.394
395
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The support for vascular and smooth muscle enrichment of the loci is strong, with multiple lines396
of evidence from independent methods and independent datasets. However, it remains likely397
that neurogenic mechanisms are also involved in migraine. For example, several lines of398
evidence from previous studies have pointed to such mechanisms5,68–71. We found some399
support for this when looking at gene expression of individual genes at the 38 loci400
(Supplementary Figure 2 and Supplementary Table 25), where many specific genes were401
active in brain tissues. While we did not observe statistically significant enrichment in brain402
across all loci, it may be that more associated loci are needed to detect this. Alternatively, it403
could be due to difficulties in collecting appropriate brain tissue samples with enough specificity,404
or other technical challenges. Additionally, there is less clarity of the biological mechanisms for405
a brain disease like migraine compared to some other common diseases, e.g. autoimmune or406
cardio-metabolic diseases where intermediate risk factors and underlying mechanisms are407
better understood.408
409
Interestingly, some of the analyses highlight gastrointestinal tissues. Although migraine attacks410
may include gastrointestinal symptoms (e.g. nausea, vomiting, diarrhea)72 it is likely that the411
signals observed here broadly represent smooth muscle signals rather than gastrointestinal412
specificity. Smooth muscle is a predominant tissue of the intestine, yet specific smooth muscle413
subtypes were not available to test this hypothesis in our primary enrichment analyses. We414
showed instead in a range of 60 smooth muscle subtypes, that the migraine loci are expressed415
in many types of smooth muscle, including vascular (Supplementary Figure 12 and 13). These416
results, while not conclusive, suggest that the enrichment of the migraine loci in smooth muscle417
is not specific to the stomach and GI tract.418
419
Our results implicate cellular pathways and provide an opportunity to determine whether the420
genomic data supports previously presented hypotheses of pathways linked to migraine. One421
prevailing hypothesis stimulated by findings in familial hemiplegic migraine (FHM) has been that422
migraine is a channelopathy5,21. Among the 38 migraine loci only two harbor known ion channels423
(KCNK519 and TRPM820), while three additional loci (SLC24A322, ITPK123, and GJA124) can be424
linked to ion homeostasis. This further supports the findings of previous studies that in common425
forms of migraine, ion channel dysfunction is not the major pathophysiological mechanism15.426
However, more generally, genes involved in ion homeostasis could be a component of the427
genetic susceptibility. Moreover, we cannot exclude that ion channels could still be important428
contributors in migraine with aura, the form most closely resembling FHM, as our ability to429
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identify loci in this subgroup is more challenging. Another suggested hypothesis relates to430
oxidative stress and nitric oxide (NO) signaling73–75. Six genes with known links to oxidative431
stress and NO, within these 38 loci were identified (REST44, GJA145, YAP146, PRDM1647,432
LRP148, and MRVI149). This is in line with previous findings11, however, the DEPICT pathway433
analysis observed no association between NO-related reconstituted gene sets and migraine434
(FDR > 0.54, Supplementary Table 23).435
436
Notably, in the migraine subtype analyses, it was possible to identify specific loci for migraine437
without aura but not for migraine with aura. However, the heterogeneity analysis438
(Supplementary Tables 12-13) demonstrated that most of the identified loci are implicated in439
both migraine subtypes. This suggests that no loci were identified in the migraine with aura440
analysis mainly due to lack of power from the reduced sample size. Additionally, as shown by441
the LD score analysis (Supplementary Figures 5-7), the amount of heritability captured by the442
migraine with aura dataset is considerably lower than migraine without aura, such that in order443
to reach comparable power, a sample size of two- to three-times larger would be required. This444
may reflect a higher degree of heterogeneity in the clinical capture, more complex underlying445
biology, or even a larger contribution from low-frequency and rare variation to migraine risk for446
this form of the disease.447
448
In conclusion, the 38 genomic loci identified in this study support the notion that factors in449
vascular and smooth muscle tissues contribute to migraine pathophysiology and that the two450
major subtypes of migraine, migraine with aura and migraine without aura, have a partially451
shared underlying genetic susceptibility profile.452
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685
Figure 1. Manhattan plot of the primary meta-analysis of all migraine (59,674 cases vs. 316,078 controls). Each marker was tested686
for association using an additive genetic model by logistic regression adjusted for sex. A fixed-effects meta-analysis was then used to687
combine the association statistics from all 22 clinic and population-based studies from the IHGC. The horizontal axis shows the688
chromosomal position and the vertical axis shows the significance of tested markers from logistic regression. Markers with test689
statistics that reach genome-wide significance (P < 5 × 10-8) at previously known and newly identified loci are highlighted according690
to the color legend.691
692
693
694
695
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698
Figure 2. Gene expression enrichment of genes from the 38 migraine loci in GTEx tissues.699
Expression data from 1,641 samples was obtained using RNAseq for 42 tissues and three cell700
lines from the GTEx consortium. Enrichment P-values were assessed empirically for each tissue701
using a permutation procedure (100,000 replicates) and the red vertical line shows the702
significance threshold after adjusting for multiple testing by Bonferroni correction (see Online703
Methods).704
705
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706
707
Figure 3. Gene expression enrichment of genes from the 38 migraine loci in 209 tissue/cell type708
annotations by DEPICT. Expression data was obtained from 37,427 human microarray samples709
and then genes in the migraine loci were assessed for high expression in each of the annotation710
categories. Enrichment P-values were determined by comparing the expression pattern from the711
migraine loci to 500 randomly generated loci and the false discovery rate (horizontal dashed712
line) was estimated to control for multiple testing (see Online Methods). A full list of these713
enrichment results are provided in Supplementary Table 20.714
24
715
Figure 4. Enrichment of the migraine loci in sets of tissue-specific enhancers. We mapped716
credible sets from the migraine loci to sets of enhancers under active expression in 56 tissues717
and cell lines (identified by H3K27ac histone marks from the Roadmap Epigenomics64 and718
ENCODE65 projects). Enrichment P-values were assessed empirically by randomly generating a719
background set of matched loci for comparison (10,000 replicates) and the vertical dotted line is720
the significance threshold after adjusting for 56 separate tests by Bonferroni correction (see721
Online Methods).722
25
723
Figure 5. DEPICT network of the reconstituted gene sets that were found to be significantly enriched (false discovery rate < 0.05) for724
genes at the migraine loci (Online Methods). Enriched gene sets are represented as nodes with pairwise overlap denoted by the725
width of the connecting lines and empirical enrichment P-value is indicated by color intensity (darker is more significant). The 67726
significantly enriched gene sets were then clustered by similarity into 10 group nodes as shown in (a) where each group node is727
named after the most representative gene set in the group. (b) Shows one example of the enriched reconstituted gene sets that were728
clustered within the now expanded ITGB1 PPI group. A full list of the 67 significantly enriched reconstituted gene sets can be found729
in Supplementary Table 24.730
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Table 1. Individual IHGC GWA studies listed with cases and control numbers used in the primary analysis (all migraine) and in the731
subtype analyses (migraine with aura and migraine without aura). Note that chromosome X genotype data was unavailable from732
three of the individual GWA studies (EGCUT, Rotterdam III, and TwinsUK) and also partially unavailable from some of the control733
samples (specifically the GSK controls) used for the ‘German MO’ study, meaning that the number of samples analyzed on734
chromosome X was 57,756 cases and 299,109 controls. Complete data was available on the autosomes for all samples.735
736
GWA Study ID Full Name of GWA Study
All migraine Migraine with aura Migraine without aura
Cases Controls Cases Controls Cases Controls
23andMe 23andMe Inc. 30,465 143,147 - - - -
ALSPAC Avon Longitudinal Study of Parents and Children 3,134 5,103 - - - -
ATM Australian Twin Migraine 1,683 2,383 - - - -
B58C 1958 British Birth Cohort 1,165 4,141 - - - -
Danish HC Danish Headache Center 1,771 1,000 775 1,000 996 1,000
DeCODE deCODE Genetics Inc. 3,135 95,585 366 95,585 608 95,585
Dutch MA Dutch migraine with aura 734 5,211 734 5,211 - -
Dutch MO Dutch migraine without aura 1,115 2,028 - - 1,115 2,028
EGCUT Estonian Genome Center, University of Tartu 813 9,850 76 9,850 94 9,850
Finnish MA Finnish migraine with aura 933 2,715 933 2,715 - -
German MA German migraine with aura 1,071 1,010 1,071 1,010 - -
German MO German migraine without aura 1,160 1,647 - - 1,160 1,647
27
Health 2000 Health 2000 136 1,764 - - - -
HUNT Nord-Trøndelag Health Study 1,395 1,011 290 1,011 980 1,011
NFBC Northern Finnish Birth Cohort 756 4,393 - - - -
NTR/NESDA Netherlands Twin Register and the NetherlandsStudy of Depression and Anxiety 1,636 3,819 544 3,819 615 3,819
Rotterdam III Rotterdam Study III 487 2,175 106 2,175 381 2,175
Swedish Twins Swedish Twin Registry 1,307 4,182 - - - -
Tromsø The Tromsø Study 660 2,407 - - - -
Twins UK Twins UK 618 2,334 202 2,334 416 2,334
WGHS Women’s Genome Health Study 5,122 18,108 1,177 18,108 1,826 18,108
Young Finns Young Finns 378 2,065 58 2,065 157 2,065
Total: 59,674 316,078 6,332 144,883 8,348 139,622
737
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Table 2. Summary of the 38 genomic loci associated with the prevalent types of migraine. Ten loci were previously reported738
(PubMed IDs listed) and 28 are newly found in this study. For each locus, the nearest coding gene to the index SNP is given. Effect739
sizes and P-values for each SNP were calculated for each study with an additive genetic model using logistic regression adjusted for740
sex and then combined in a fixed-effects meta-analysis. For loci that contain a secondary LD-independent signal passing genome-741
wide significance, the secondary index SNP and P-value is given. For the seven loci reaching genome-wide significance in the742
migraine without aura sub-type analysis, the corresponding index SNP and P-value are also given. Evidence for significant743
heterogeneity was found at four loci (TRPM8, MRVI1, ZCCHC14, and CCM2L) so for those we present the results of a random-744
effects model.745
746
Locus
Rank
Nearest
coding gene Chr Index SNP
Minor
Allele MAF
All Migraine Secondary signal Migraine without aura Previous
Publication
PMIDOR [95% CI] P Index SNP P Index SNP P
1 LRP1 12 rs11172113 C 0.42 0.90 [0.89-0.91] 5.6 x 10-49 rs7961602 2.1 x 10-11 rs11172113 4.3 x 10-16 21666692
2 PRDM16 1 rs10218452 G 0.22 1.11 [1.10-1.13] 5.3 x 10-38 rs12135062 3.7 x 10-10 - - 21666692
3 FHL5 6 rs67338227 T 0.23 1.09 [1.08-1.11] 2.0 x 10-27 rs2223239 3.2 x 10-10 rs7775721 1.1 x 10-12 23793025
4 TSPAN2 1 rs2078371 C 0.12 1.11 [1.09-1.13] 4.1 x 10-24 rs7544256 8.7 x 10-09 rs2078371 7.4 x 10-09 23793025
5 TRPM8 2 rs10166942 C 0.20 0.94 [0.89-0.99] 1.0 x 10-23 rs566529 2.5 x 10-09 rs6724624 1.1 x 10-09 21666692
6 PHACTR1 6 rs9349379 G 0.41 0.93 [0.92-0.95] 5.8 x 10-22 - - rs9349379 2.1 x 10-09 22683712
7 MEF2D 1 rs1925950 G 0.35 1.07 [1.06-1.09] 9.1 x 10-22 - - - - 22683712
8 SLC24A3 20 rs4814864 C 0.26 1.07 [1.06-1.09] 2.2 x 10-19 - - - - -
9 FGF6 12 rs1024905 G 0.47 1.06 [1.04-1.08] 2.1 x 10-17 - - rs1024905 2.5 x 10-09 -
10 C7orf10 7 rs186166891 T 0.11 1.09 [1.07-1.12] 9.7 x 10-16 - - - - 23793025
11 PLCE1 10 rs10786156 G 0.45 0.95 [0.94-0.96] 2.0 x 10-14 rs75473620 5.8 x 10-09 - - -
12 KCNK5 6 rs10456100 T 0.28 1.06 [1.04-1.07] 6.9 x 10-13 - - - - -
13 ASTN2 9 rs6478241 A 0.36 1.05 [1.04-1.07] 1.2 x 10-12 - - rs6478241 1.2 x 10-10 22683712
14 MRVI1 11 rs4910165 C 0.33 0.94 [0.91-0.98] 2.9 x 10-11 - - - - -
15 HPSE2 10 rs12260159 A 0.07 0.92 [0.89-0.94] 3.2 x 10-10 - - - - -
16 CFDP1 16 rs77505915 T 0.45 1.05 [1.03-1.06] 3.3 x 10-10 - - - - -
17 RNF213 17 rs17857135 C 0.17 1.06 [1.04-1.08] 5.2 x 10-10 - - - - -
18 NRP1 10 rs2506142 G 0.17 1.06 [1.04-1.07] 1.5 x 10-09 - - - - -
29
19 GPR149 3 rs13078967 C 0.03 0.87 [0.83-0.91] 1.8 x 10-09 - - - - -
20 JAG1 20 rs111404218 G 0.34 1.05 [1.03-1.07] 2.0 x 10-09 - - - - -
21 REST 4 rs7684253 C 0.45 0.96 [0.94-0.97] 2.5 x 10-09 - - - - -
22 ZCCHC14 16 rs4081947 G 0.34 1.03 [1.00-1.06] 2.5 x 10-09 - - - - -
23 HEY2 6 rs1268083 C 0.48 0.96 [0.95-0.97] 5.3 x 10-09 - - - - -
24 WSCD1 17 rs75213074 T 0.03 0.89 [0.86-0.93] 7.1 x 10-09 - - - - -
25 GJA1 6 rs28455731 T 0.16 1.06 [1.04-1.08] 7.3 x 10-09 - - - - -
26 TGFBR2 3 rs6791480 T 0.31 1.04 [1.03-1.06] 7.8 x 10-09 - - - - 22683712
27 ITPK1 14 rs11624776 C 0.31 0.96 [0.94-0.97] 7.9 x 10-09 - - - - -
28 ADAMTSL4 1 rs6693567 C 0.27 1.05 [1.03-1.06] 1.2 x 10-08 - - - - -
29 CCM2L 20 rs144017103 T 0.02 0.85 [0.76-0.96] 1.2 x 10-08 - - - - -
30 YAP1 11 rs10895275 A 0.33 1.04 [1.03-1.06] 1.6 x 10-08 - - - - -
31 MED14 X rs12845494 G 0.27 0.96 [0.95-0.97] 1.7 x 10-08 - - - - -
32 DOCK4 7 rs10155855 T 0.05 1.08 [1.05-1.12] 2.1 x 10-08 - - - - -
33 LRRIQ3 1 rs1572668 G 0.48 1.04 [1.02-1.05] 2.1 x 10-08 - - - - -
34 CARF 2 rs138556413 T 0.03 0.88 [0.84-0.92] 2.3 x 10-08 - - - - -
35 ARMS2 10 rs2223089 C 0.08 0.93 [0.91-0.95] 3.0 x 10-08 - - - - -
36 IGSF9B 11 rs561561 T 0.12 0.94 [0.92-0.96] 3.4 x 10-08 - - - - -
37 MPPED2 11 rs11031122 C 0.24 1.04 [1.03-1.06] 3.5 x 10-08 - - - - -
38 NOTCH4 6 rs140002913 A 0.06 0.91 [0.88-0.94] 3.8 x 10-08 - - - - -
30
Online Methods747
Quality Control. The 22 individual GWA studies were subjected to pre-established quality748
control (QC) protocols as recommended elsewhere76,77. Differences in genotyping chips, DNA749
quality and genotype calling pipelines necessitated that QC parameters were tuned separately750
to be appropriate for each individual study. At a minimum, we excluded markers with751
excessively high missingness rates (> 5%), low minor allele frequency (< 1%), and failing a test752
of Hardy-Weinberg equilibrium. We also excluded individuals with a high proportion of missing753
genotypes (> 5%) and used identity-by-descent (IBD) estimates to remove individuals that were754
highly related (IBD>0.185) to others in the sample. A summary of the genotyping platforms,755
quality control, imputation protocols and association analysis methods used in each individual756
GWA study is provided in Supplementary Table 3. All case/control sets that were genotyped757
separately were first quality controlled independently and then again after merging the data.758
759
To control for population stratification within each individual GWA study, we merged the760
genotypes passing quality control filters with HapMap III genotype data from three populations;761
European (CEU), Asian (CHB + JPT) and African (YRI). We then performed a principal762
components analysis on the merged dataset and excluded any (non-European) population763
outliers from our studies. To control for any further (sub-European) population structure, we764
performed a second principal components analysis on the genotype data from each GWA study765
separately to ensure that cases and controls were clustering together. We then tested whether766
any principal components were significantly associated with the phenotype using logistic767
regression. Any principal components that were significantly associated were then included as768
covariates in the model when generating the final association test statistics for the migraine769
meta-analysis. The specific principal components adjusted for in each individual GWA study are770
listed in Supplementary Table 4.771
772
Imputation. Following GWA study-level QC, the data underwent a phasing step whereby773
haplotypes for each individual were statistically estimated using (in most instances) the program774
SHAPEIT78. Missing genotypes were then imputed into these haplotypes using the program775
IMPUTE279 and a mixed-population reference panel provided by the 1000 Genomes Project16.776
All study samples were imputed using the March 2012 (phase I, v3 release or later) 1000777
Genomes reference panel. A minority of contributing GWA studies used alternative programs for778
phasing and imputation such as BEAGLE80, MACH81, and MINIMAC82 or some in-house custom779
software. A full list of software and procedures used are provided in Supplementary Table 3.780
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781
Statistical Analysis. Individual study association analyses were implemented using logistic782
regression with an additive model on the imputed dosage of the effect allele. All models were783
adjusted for sex and other relevant covariates. Age information was not available for individuals784
from all studies therefore we were not able to adjust for it in our models. However, we note that785
all of the GWA studies were comprised of adults past the typical age of onset, hence age is at786
most a non-confounding factor and false positive rates would not be affected by its787
inclusion/exclusion. Furthermore, including such covariates can be sub-optimal, reducing power788
to detect genetic associations. To control for sub-European population structure, we also789
included in the model any principal components that were significantly associated with the790
phenotype (Supplementary Table 4). The programs used for performing the association791
analyses were either SNPTEST, PLINK or R (see URLs). To combine association summary792
statistics from all individual studies we used the program GWAMA (URLs) to perform a fixed-793
effects meta-analysis weighted by the inverse variance to obtain a combined effect size,794
standard error and p-value at each marker. We excluded markers in any individual study that795
had low imputation quality scores (IMPUTE2 INFO < 0.6 or MACH r2 < 0.6) or low minor allele796
frequency (MAF < 0.01). Additionally, we filtered out any marker that was missing from more797
than half the individual studies (missing from 12 or more out of 22 studies) and also markers798
exhibiting high levels of heterogeneity as identified by a high heterogeneity index (i2 > 0.75).799
After applying all filters, this left 8,045,569 total markers tested in the meta-analysis.800
801
Chromosome X meta-analysis. Due to the different ploidy of males and females, the X802
chromosome required a different statistical model; we applied a model of X-chromosome803
inactivation (XCI) that assumes an equal effect of alleles in both males and females. This XCI804
model was achieved by scaling male dosages to the range 0-2 to match that of females. In total,805
57,756 cases and 299,109 controls were available for the X-chromosome analysis806
(Supplementary Table 1). The reduced sample size compared to the autosomal data occurred807
because some of the individual GWA studies (EGCUT, Rotterdam III, Twins UK, and 846808
controls from GSK for the ‘German MO’ study) did not contribute chromosome X data.809
810
Defining Credible Sets. Within each migraine-associated locus, we defined a credible set of811
variants that could be considered 99% likely to contain a causal variant. The method has been812
introduced in detail elsewhere52,58 and a full derivation is outlined again briefly in the813
Supplementary Note. This method assumes that there is one and only one causal variant in the814
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locus. For loci that contain a secondary independent signal, we conservatively mapped only the815
primary signal.816
817
LD score regression analysis. We conducted a univariate heritability analysis based on818
summary statistics using LD score regression (LDSC) v1.0.055. For this analysis, high-quality819
common SNPs were extracted from the summary statistics by filtering the data using the820
following criteria: presence among the HapMap Project Phase 3 SNPs83, allele matching to821
1000 Genomes data, no strand ambiguity, INFO score > 0.9, MAF >= 1%, and missingness less822
than two thirds of the 90th percentile of total sample size. The HLA region (chromosome 6, from823
25 - 35 Mb) was excluded from the analysis. From this data, we used LDSC to quantify the824
proportion of the total inflation in chi-square statistics that can be ascribed to polygenic825
heritability by calculating the ratio of the LDSC intercept estimate and the chi-square mean826
using the formula described in the original publication55.827
828
eQTL Credible Set Overlap Analysis. To test whether the association statistics across each of829
the 38 migraine loci could be explained by credible overlapping eQTL signals, we used two830
previously published eQTL microarray datasets. The first dataset consisted of 3,754 samples831
from peripheral venous blood84 and the second was from a meta-analysis of human brain cortex832
studies of 550 samples85. From both studies we obtained summary statistics from an833
association test of putative cis-eQTLs between all SNP-transcript pairs within a 1-Mb window of834
each other. To test for overlapping eQTLs, we used credible sets of markers (see Defining835
Credible Sets) at each of the 38 distinct migraine loci. Then for the most significant eQTLs (P <836
1x10-4) found to genes within a 1Mb window of each migraine credible set, we created an837
additional credible set of markers for each eQTL. We then tested (using Spearman’s rank838
correlation) whether there was a significant correlation between the association test-statistics in839
each migraine credible set compared to the expression test-statistics in each overlapping eQTL840
credible set. Significant correlation between a migraine credible set and an eQTL credible set841
was taken as evidence of the migraine locus tagging a real eQTL. We determined the842
significance threshold to account for multiple testing by Bonferroni correction.843
844
Enhancer Enrichment Analysis. Markers of gene regulation were defined using ChIP-seq845
datasets produced at the Broad Institute and the University of California at San Diego as part of846
ENCODE65 and the NIH Roadmap Epigenome64 projects. Based on the histone H3K27ac847
signal, which identifies active enhancers, we processed data from 56 cell lines and tissue848
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samples to identify celltype- or tissue-specific enhancers, which we define as the 10% of849
enhancers with the highest ratio of reads in that cell or tissue type divided by the total reads86. A850
description of all 56 tissues/cell types is provided in Supplementary Table 21 and the raw851
enhancer data can be downloaded at http://www.epigenomeatlas.org.852
853
We mapped the candidate causal variants at each migraine associated locus to these enhancer854
sequences, and compared the overlap observed with tissue specific enhancers relative to all855
enhancers using a background of 10,000 randomly selected sets of SNPs of equal size as the856
original locus. We restricted the background selection to common variants (MAF>1%) from857
1000 Genomes that also passed our quality control filters in the meta-analysis (in other words,858
to only allow the selection of SNPs that had an a priori chance of being associated). The859
selection procedure then involved randomly selecting regions of the genome that were of860
equivalent length and containing an equivalent density of enhancers as found in the original861
locus. Once an appropriate region was found, a set of SNPs was randomly selected to match862
the number of SNPs in the credible set for that locus. If the selected SNPs happened to fall in863
an equal number of enhancer sites (of any tissue type) as that of the credible set of SNPs from864
the original locus, then the selected set of SNPs was accepted and added to the background set865
of SNPs for comparison. If the number of enhancers overlapping with the selected SNPs didn’t866
match, the randomized selection procedure was repeated until an appropriate comparison set of867
SNPs was selected. This selection procedure was repeated for each locus 10,000 times to868
obtain an empirical null distribution. The significance of the observed enrichment was then869
estimated from the empirical distribution by calculating the proportion of replicates that were870
greater than the observed value (i.e. Empirical P-value = [R + 1]/[N + 1] where R is the number871
out of all N replicates that were higher than the observed enrichment). Finally, we used872
Bonferroni correction to adjust for multiple testing of 56 tissue/cell types (P < 8.9 x 10-4).873
874
DEPICT reconstituted gene-set enrichment analysis. DEPICT62 (Data-driven Expression875
Prioritized Integration for Complex Traits) is a computational tool, which, given a set of GWAS876
summary statistics, allows prioritization of genes in associated loci, enrichment analysis of877
reconstituted gene sets, and tissue enrichment analysis. DEPICT was run using as input 124878
independent genome-wide significant SNPs (PLINK clumping parameters: --clump-p1 5e-8 --879
clump-p2 1e-5 --clump-r2 0.6 --clump-kb 250. Note - rs12845494 and rs140002913 could not be880
mapped). LD distance (r2 > 0.5) was used to define locus boundaries (note that this locus881
definition is different than used elsewhere in the text) yielding 37 autosomal loci comprising 78882
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genes. DEPICT was run using default settings, that is, 500 permutations for bias adjustment, 20883
replications for false discovery rate estimation, normalized expression data from 77,840884
Affymetrix microarrays for gene set reconstitution (see reference87), 14,461 reconstituted gene885
sets for gene set enrichment analysis, and testing 209 tissue/cell types assembled from 37,427886
Affymetrix U133 Plus 2.0 Array samples for enrichment in tissue/cell type expression.887
888
DEPICT identified 76 reconstituted gene sets that are significantly enriched (FDR < 5%) for889
genes found among the 38 migraine associated loci. Post-analysis, we omitted reconstituted890
gene sets in which genes in the original gene set were not nominally enriched (Wilcoxon rank-891
sum test) because, by design, genes in the original gene set are expected to be enriched in the892
reconstituted gene set; lack of enrichment therefore complicates interpretation of the893
reconstituted gene set because the label of the reconstituted gene set will be inaccurate.894
Therefore the following reconstituted gene sets were removed from the results (Wilcoxon rank-895
sum P-values in parentheses): MP:0002089 (0.01), MP:0002190 (0.16), ENSG00000151577896
(0.21), ENSG00000168615 (0.94), ENSG00000143322 0.70), ENSG00000112531 (0.04),897
ENSG00000161021 (0.10), ENSG00000100320 (0.43). We also removed an association898
identified to another gene set (ENSG00000056345 PPI, P = 1.7×10-4, FDR = 0.04) because it is899
no longer part of the Ensembl database. These post-analysis filtering steps left us with 67900
significantly enriched reconstituted gene sets. The Affinity Propagation tool88 was finally used to901
cluster related reconstituted gene sets into 10 groups (script to produce the network diagram902
can be downloaded from https://github.com/perslab/DEPICT).903
904
DEPICT tissue enrichment analysis. For the tissue enrichment analysis, DEPICT incorporates905
data from 37,427 human microarray samples captured on the Affymetrix HGU133a2.0 platform.906
These are used to test whether genes in the 38 migraine loci are highly expressed in 209907
tissues/cell types with Medical Subject Heading (MeSH) annotations. The annotation procedure908
and method for normalizing expression profiles across annotations is outlined in the original909
publication62. The tissue/cell type enrichment analysis algorithm is conceptually identical to the910
gene set enrichment analysis algorithm whereby enrichment P-values are calculated empirically911
using 500 permutations for bias adjustment and 20 replications for false discovery rate912
estimation.913
914
GTEx tissue enrichment analysis. Credible sets were generated for all 38 migraine loci (with915
P < 5 x 10-8) and corresponding gene sets for each locus were then generated by taking all916
35
genes within 50 kilobases of a credible set SNP. Genes identified in this way were then917
analyzed for tissue enrichment using publicly available expression data from pilot phase of the918
Genotype-Tissue Expression project (GTEx)61, version 3. In the pilot phase dataset, postmortem919
samples from 42 human tissues and three cell lines across 1,641 samples (Supplementary920
Table 16) have been used for bulk RNA sequencing according to a unified protocol. All samples921
were sequenced using Illumina 76 base-pair paired-end reads.922
923
Collapsed reads per kilobase per million mapped reads (RPKM) values for each of the 52,577924
included transcripts, filtered for unique HGNC IDs (n = 20,932), were organized by tissue and925
individual (ntissues = 45, nsamples = 1,641). By this process we also excluded transcripts from any926
non-coding RNAs. All transcripts were ranked by mean RPKM across all samples, and 100,000927
permutations of each credible set gene list were generated by selecting a random transcript for928
each entry in the credible set within +/-100 ranks of the transcript for that gene. For each929
sample, the RPKM values were converted into ranks for that transcript, and sums of ranks930
within each tissue were computed for each gene. P-values for each tissue were calculated by931
taking the total number of cases where the gene list of interest had a lower sum of ranks than932
the permuted sum of ranks, and dividing by the total number of permutations. To assess the933
significance of the enrichment after testing multiple tissues, we used a Bonferroni correction934
adjusted for the number of independent tissues, estimated via the matSpD tool89 to arrive at 27935
independent tests and a significance threshold of P < 1.90 x 10-3.936
937
Specificity of individual gene expression in GTEx tissues. For the individual-gene938
expression analysis, we selected the closest gene to the index SNP at each migraine locus and939
then investigated expression activity of each of these genes in the collection of available940
tissues. As the number of samples for some tissues was small, we grouped individual tissues941
into four categories; brain, vascular, gastrointestinal, and other tissues (Supplementary Table942
16). Then for each selected gene, we tested whether the average expression (mean RPKM)943
was significantly higher in a particular tissue group compared to the “other tissues” category.944
We assessed significance using a one-tailed t-test and used Bonferroni correction to control for945
multiple testing for all 114 tests (38 genes × 3 tissue groups). While some genes were observed946
to be significantly expressed in multiple tissue groups, we determined that a gene was tissue-947
specific if it was only expressed highly in one tissue group (i.e. brain, vascular, or948
gastrointestinal, Supplementary Table 25).949
950
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eQTL credible set analysis in GTEx tissues. For all tissues and transcripts, we identified951
genome-wide significant (P < 2 x 10-13) cis-eQTLs within a 1Mb window of each transcript and952
created credible sets (see Defining Credible Sets) for each eQTL locus identified in each953
tissue. Then, for each eQTL credible set that contained markers that overlapped with a migraine954
credible set, we tested using Spearman’s rank correlation if the test statistics between the two955
overlapping credible sets were significantly correlated. Significant correlation between a956
migraine credible set and an eQTL credible set was taken as evidence of the migraine locus957
tagging a real eQTL. Multiple testing was controlled for using Bonferroni correction.958
959
Across the GTEx collection of tissues we found 35 significant cis-eQTLs within a 1Mb window of960
the 38 migraine loci, however, upon creating credible sets, seven of these still contained SNPs961
that overlapped with any of the migraine credible sets. Testing these seven eQTL credible sets962
as described above found that the correlation was significant (P < 7.1 x 10-3) for eQTLs to four963
tissues (Lung, Thyroid, Tibial Artery, and Aorta) at two migraine loci (HPSE2 and HEY2)964
Supplementary Table 19 and Supplementary Figure 15.965
966
Heterogeneity analysis of migraine subtypes. To discover if heterogeneity between the967
migraine subtypes might have affected our ability to identify new loci, we performed an968
additional meta-analysis using a subtype-differentiated approach that allows for different allelic969
effects between the two groups57. Since a large proportion of the controls were shared in the970
original migraine with aura and migraine without aura samples (see Table 1), for this analysis971
we created two additional subsets of the migraine subtype data that contained no overlapping972
controls between the two new subsets (Supplementary Table 12). The new migraine with aura973
subset consisted of 4,837 cases and 49,174 controls and the new migraine without aura subset974
consisted if 4,833 cases and 106,834 controls. Then using the association test statistics from975
each of the individual GWA studies listed, we performed the subtype-differentiated meta-976
analysis as implemented in GWAMA (see URLs).977
978
To assess the amount of heterogeneity observed, we chose the 44 LD independent SNPs that979
were associated with migraine and examined the results of the subtype-differentiated meta-980
analysis. We observed that only seven out of the 44 SNPs showed evidence for heterogeneity981
in the subtype-differentiated test (Heterogeneity P-value < 0.05, Supplementary Table 13).982
This suggests that most of the identified loci are truly affecting risk for both migraine with aura983
37
and migraine without aura even though we may not yet have power to detect their association in984
the subset meta-analyses.985
986
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